Full Description
Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.
Table of Contents
Front Matter
Summary
1 Introduction
2 Profile of Rare Diseases
3 Regulatory Framework for Drugs for Rare Diseases
4 Discovery Research for Rare Diseases and Orphan Product Development
5 Development of New Therapeutic Drugs and Biologics for Rare Diseases
6 Coverage and Reimbursement: Incentives and Disincentives for Product Development
7 Medical Devices: Research and Development for Rare Diseases
8 Toward an Integrated Approach to Accelerating Research and Product Development for Rare Diseases
References
Appendix A: Study Activities
Appendix B: Innovation and the Orphan Drug Act, 1983-2009: Regulatory and Clinical Characteristics of Approved Orphan Drugs
Appendix C: Medicare Part D Coverage and Reimbursement of Orphan Drugs
Appendix D: Glossary, Abbreviations, and Public Laws
Appendix E: Rare Diseases Clinical Research Network
Appendix F: Advocacy Group Approaches to Accelerating Research and Product Development: Illustrative Examples
Appendix G: Committee and Staff Biographies
Index
Contents
1 Front Matter; 2 Summary; 3 1 Introduction; 4 2 Profile of Rare Diseases; 5 3 Regulatory Framework for Drugs for Rare Diseases; 6 4 Discovery Research for Rare Diseases and Orphan Product Development; 7 5 Development of New Therapeutic Drugs and Biologics for Rare Diseases; 8 6 Coverage and Reimbursement: Incentives and Disincentives for Product Development; 9 7 Medical Devices: Research and Development for Rare Diseases; 10 8 Toward an Integrated Approach to Accelerating Research and Product Development for Rare Diseases; 11 References; 12 Appendix A: Study Activities; 13 Appendix B: Innovation and the Orphan Drug Act, 1983-2009: Regulatory and Clinical Characteristics of Approved Orphan Drugs; 14 Appendix C: Medicare Part D Coverage and Reimbursement of Orphan Drugs; 15 Appendix D: Glossary, Abbreviations, and Public Laws; 16 Appendix E: Rare Diseases Clinical Research Network; 17 Appendix F: Advocacy Group Approaches to Accelerating Research and Product Development: Illustrative Examples; 18 Appendix G: Committee and Staff Biographies; 19 Index
